Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

MGI Tech Co., Ltd.. (2/27/20). "Press Release: MGI and Sophia Genetics Partner to Provide Solutions to Interpret Genomic Data". San José, CA.

Organisations Organisation MGI Tech Co., Ltd.
  Group BGI (CN) (Group)
  Organisation 2 Sophia Genetics S.A.
  Group Sophia Genetics (Group)
Products Product Sophia DDM (Data Driven Medicine)
  Product 2 DNBSEQ® technology
Persons Person Jiang, Hui (BGI 202002 COO of MGI)
  Person 2 Puylaert, Kevin (Sophia Genetics 202002 VP Business Development)

MGI, part of the global genomics leader BGI Group, announced an agreement with SOPHiA GENETICS to provide MGI’s customers access to the SOPHiA Platform for data analysis and interpretation. By combining MGI’s DNBSEQ™ sequencing technology with SOPHiA’s Platform, MGI provides an effective solution for clinical researchers and further drives adoption of MGI’s genetic sequencers.

Under the terms of the non-exclusive agreement, MGI’s customers will have the ability to utilize SOPHiA to convert various assays already validated in the past onto DNBSEQ™ based sequencers. The SOPHiA Platform supports more than 250 genomic applications and over 1,000 healthcare institutions around the world.

“MGI recognizes that analysis and interpretation of MPS data present challenges to researchers and clinicians, so we are excited to offer the bundled solution of our DNBSEQ™ sequencers with the sophisticated SOPHiA Platform. Our DNBSEQ™ and CoolMPS technologies are not only highly accurate, affordable and sensitive, but also very versatile and easy to adapt to any existing library preparation methodologies. This will enable existing MPS users to use MGI DNBSEQ™ sequencers to advance their research and translational genomic goals,” said Dr. Hui Jiang, COO of MGI.

MGI customers will also benefit from the SOPHiA Set-Up Program to start up new assays or transfer their existing assays into DNBSEQ sequencing platforms. The program is designed to support the implementation of MPS-based testing for somatic and germline assays. The Set-Up Program is a robust process that establishes and demonstrates the analytical performance of a genomic application to save time, money and resources that can ultimately be translated to better patient care.

“We are proud that MGI is working with SOPHiA GENETICS to provide their customers with our universal platformto analyze genomic data produced from its sequencers,” said Kevin Puylaert, VP of Business Development at SOPHiA GENETICS. “This further supports essential access to highly accurate data that healthcare institutions require for reliable testing results. This is an additional effort on our mission to continuously democratize Data-Driven Medicine around the world.”

Record changed: 2020-03-02


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for BGI (CN) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top